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the GTV was undertaken on the images to quantify entropy, 
uniformity, mean grey-level intensity, kurtosis, standard 
deviation of histogram and skewness for fine to coarse 




Results: To date, 23 patients from 21 centres entered in the 
trial have been analysed. Mean Grey Level <399.745, 
Skewness >2.215, Kurtosis >0.6 were associated with 
improved PFS (p=0.0227, p=0.0218, p=0.0460 respectively) 
for medium filter 3.0. For filter 4.0, improved PFS was 
associated with Mean Grey Level <454.055 (p=0.0227) and 
Skewness >0.840 (p=0.0371). Mean Grey Levels of <565.535 
(p=0.0251) and <542.5(p=0.0251) were associated with 
improved PFS for filters 5.0 and 6.0 respectively. For OS, 
mean grey levels of <34.845 (p=0.0182), <399.745 (p=0.0381) 
and <454.055 (p=0.0381) were associated with improved 
survival for filters 0.0, 3.0 and 4.0 respectively. An entropy 
level <5.6 was also found to be significant (p=0.0428) for 
improved overall survival using filter 2.0. 
 
Conclusion : Normal 0 false false false EN-GB JA X-NONE  
We have shown using a 10% sample of the overall database 
available that CTimage heterogeneity factors are associated 
with PFS and OS for patients frommultiple centres. 
Preliminary results therefore suggest that in the future itmay 
be possible to make clinical treatment decisions based on the 
CT imageheterogeneity of a tumour volume. This will be 
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Purpose or Objective: To evaluate the feasibility and clinical 
results of stereotactic body radiation therapy (SBRT) in the 
treatment of hepatocellular carcinoma (HCC) in patients 
unsuitable or failing to standard loco-regional therapies. 
 
Material and Methods: Patients with < 3 inoperable HCC 
lesions with < 6 cm diameter were treated with SBRT. 
Prescription dose was adapted according to tumor size and 
global liver function and comprised 48-36 Gy in 3 fractions or 
40 Gy in 5 fractions (prescribed on 80 % isodose). Primary 
endpoint included in-field (LC) local control and toxicity. 
Secondary endpoints were overall (OS), cancer-specific (CSS) 
and progression-free survival (PFS). 
 
Results: 82 patients with 120 HCC lesions were treated. 
Median age was 70 (range 44-90). Most of the patients had 
Child-Pugh A5-A6 cirrhosis (80.4%), Barcelona Clinic Liver 
Cancer classification 0-A-B (93%). Median lesion size was 22 
mm (range 7-120 mm). Most lesion were in the left lobe 
(65%). In most patients SBRT was the first local treatment 
(82%). Up to 7% of patients had portal vein thrombosis. 
Median observation time was 14 months. Actuarial 1-year LC, 
PFS, CSS and OS were 76.7% (95%CI:40-92.5%), 13.5% 
(95%CI:4.9-26-4), 92.1% (95%CI:81.8-96.7%) and 78% 
(95%CI:66.4-86%), respectively. Up to 18 patients (22%) 
experienced G3-G4 acute toxicity and 1 case of G5 toxicity 
was reported. Four cases of classical Radiation-induced liver 
disease (RILD) were reported, while 21 patients experienced 
a modification of Child-Pugh classification (25%), mostly of 2-
3 points. On multivariate analysis, no factors were predictive 
for LC while initial Child-Pugh class and > 2 points Child-Pugh 
classification modification predicted for OS and CSS. 
 
 
Conclusion: SBRT is a safe and effective treatment option for 
inoperable HCC, with acceptable LC rate and toxicity profile. 
Limiting toxic events may have prognostic significance. 
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Purpose or Objective: Margin-directed neoadjuvant 
pancreatic cancer radiotherapy aims to improve rates of 
surgical resection with clear margins. The target volume 
encompasses adjacent/infiltrated vasculature but methods 
used in its definition have varied and in some cases lacked 
reproducibility. SPARC (UKCRN ID: 18496) is a CRUK-funded 
[grant number C43735/A18787] phase 1 study of pre-
operative Margin-Intense Stereotactic Radiotherapy for 
patients with Borderline-Resectable Pancreatic Cancer 
(BRPC) and incorporates a comprehensive Radiotherapy 
Quality Assurance protocol to ensure consistency in target 
definition and radiotherapy delivery. 
 
Material and Methods: On a BRPC test case ‘Gold-Standard’ 
structures were defined by two clinical oncologists and one 
radiologist. A detailed method was specified for derivation of 
CTV_M, the target structure for the margin-directed boost. 
GTV_T was contoured to define gross tumour. Conformity 
analysis metrics were generated to compare structures 
produced independently by six clinical oncologist 
investigators with the Gold-Standard. 
 
 
Results: Gold-Standard and median investigator volumes for 
GTV_T were 2.1cc and 5.35cc (IQR 4.1-6.7) respectively, and 
1.1cc and 1.3cc (IQR 0.9-1.5) for CTV_M. Median distance 
between centre of mass of Gold-Standard and investigator 
volumes was 0.32cm (0.19-0.47cm) for GTV_T and 0.24cm 
(0.09-0.36cm) for CTV_M. Median DICE conformity 
coefficients for GTV_T and CTV_M were 0.51 (0.40-0.60) and 
0.68 (0.60-0.75), median discordance indices (measurement 
of over-inclusive contouring) for GTV_T and CTV_M were 0.64 
(0.54-0.74) and 0.39 (0.19-0.44). 
 
Conclusion: The investigator CTV_M structures showed less 
inter-observer variance in volume and less deviation from the 
Gold-Standard compared with the investigator GTV_T 
structures. The method of CTV_M definition appears 
consistently reproducible but accurate delineation of 
pancreatic malignancies remains difficult and oncologists 
should have expert radiology support in this task. 
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Purpose or Objective: Adjuvant radiotherapy (RT) is 
frequently used in the treatment of biliary tract cancer 
(BTC). Accurate target volume delineation is crucial for 
tumor control and avoiding unnecessary damages. However, 
there is no consensus on delineation of clinical target volume 
(CTV) in BTC. The aim of our study is to review the published 
details of the CTV contouring practice and to propose criteria 
for the CTV delineation in the adjuvant RT of BTC. 
 
Material and Methods: A comprehensive literature search 
was performed using the ‘‘PubMed’’ and ‘‘Google Scholar’’ 
databases, and articles on BTC radiotherapy that provided 
descriptions of the CTV contouring were selected. The 
descriptions were thoroughly reviewed and compared to 
identify the areas of strong consensus on their inclusion in 
the CTV among different authors and the areas with more 
variability that require individual decisions when creating the 
CTV. Nodal CTV was considered as well as the microscopic 
tumor spread (MTS) into the liver and along the bile-duct 
system. Three types of BTC were considered: intrahepatic 
cholangiocarcinoma (IHC), extrahepatic cholangiocarcinoma 
(EHC) and gall bladder cancer (GBC). Based on the analyzed 
data on contouring practice, we proposed a set of guidelines 
for the CTV delineation. 
 
Results: Out of 52 studies that reported the use of adjuvant 
RT in BTC, 17 were finally included: one prospective, 13 
retrospective and 3 reviews. 1. EHC and GBC (14 relevant 
studies): the porta hepatic and celiac lymph nodes (LN) were 
always included into the CTV (100% accordance), the 
pancreaticoduodenal LN were included in all but one study 
(93%), whereas for paraaortic LN no agreement exists: four 
authors (28.5%) mentioned them to be included. Additionally, 
one author (7%) included the superior mesentery artery nodes 
for ampullary location. Some data regarding the MTS was 
reported in three studies: tumor bed was encompassed with 1 
cm, 1-1.5 cm and 2-3 cm margin, respectively. One author 
mentioned 2-4 cm margin to account for MTS along the bile 
duct. 2. IHC (3 studies): a strong consensus (100% 
accordance) exists on including the porta hepatic, celiac and 
pancreaticoduodenal LN into the CTV. Only one author 
mentioned the para-aortic LNS to be included. Regarding the 
MTS: two authors used 1 cm margin to cover the tumor bed 
and resection margin of liver and one author mentioned 2-4 





This is the first proposal of the CTV contouring guidelines for 
adjuvant RT for BTC. We recommend the coverage of porta 
hepatic, celiac and pancreaticoduodenal LN in all cases of 
BTC. Para-aortic LN coverage should be considered especially 
in EHC and GBC, and its use should be individualized. Tumor 
bed and resection margin of liver should be encompassed 
